Factors associated with stockout of Nevirapine syrup in Oshana Region, Namibia.
Nevirapine syrup
Stock out
supply chain
Journal
Journal of public health in Africa
ISSN: 2038-9922
Titre abrégé: J Public Health Afr
Pays: Italy
ID NLM: 101586943
Informations de publication
Date de publication:
31 Dec 2019
31 Dec 2019
Historique:
received:
28
01
2019
accepted:
17
10
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Infants who are born with HIV/AIDS is still a public health concern in developing countries, especially in Sub Saharan Africa. In Namibia, it is estimated that the prevalence rate of HIV pregnant women is around 17.2%, makes it to be among the countries with the highest prevalence rates among HIV women in sub-Saharan Africa (SSA). Some improvement regarding Prevention of Mother to Child Transmission has been made, however, frequent stock out of Nevirapine syrup continues to slow down, government efforts to foster the emergence of an HIV-free generation of Namibians. Given the nature of current conditions, justification exists for a study to determine the factors associated with stock out of Nevirapine (NVP) syrup.Mixed method was employed. In which descriptive approach was employed to acquire data from a period of five years retrospectively (2012-2016) and informants from different levels of supply chain in Oshana region. Initial, order receiving is not a predictor of NVP syrup. Lack of pharmaceutical knowledge is the biggest challenge which leads to sporadic stock out of NVP syrup. Pharmaceutical knowledge of ordering NVP syrup is needed to prevent stock out of NVP syrup. It is a recommendation of this study that training is needed for staffs who are involved in ordering of pharmaceutical items.
Identifiants
pubmed: 32257074
doi: 10.4081/jphia.2019.1035
pmc: PMC7118430
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1035Informations de copyright
©Copyright: the Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare no potential conflict of interest.
Références
Iran J Pharm Res. 2012 Spring;11(2):565-72
pubmed: 24250480
Kolner Z Soz Sozpsychol. 2017;69(Suppl 2):107-131
pubmed: 28989188
J Pharm Policy Pract. 2014 Apr 22;7:3
pubmed: 25848543
Health Policy Plan. 2017 Oct 1;32(8):1127-1134
pubmed: 28541542
J Pharm Policy Pract. 2016 Mar 31;9:11
pubmed: 27042314
PLoS One. 2019 Mar 12;14(3):e0212405
pubmed: 30861000
Glob Health Sci Pract. 2016 Mar 25;4(1):165-77
pubmed: 27016552